Regencell Bioscience(US:RGC) Changjiang Securities·2025-06-19 11:28Investment Rating - The industry investment rating is "Positive" and maintained [8] Core Viewpoints - The successful completion of China's first invasive brain-computer interface (BCI) clinical trial marks the country as the second globally to enter this stage, following the United States [2][5] - The stock price of Regenative Medicine (RGC) surged by 283.12% to $60 on June 16, indicating strong market interest in BCI technology [2][5] - The BCI medical application market is projected to reach between $40 billion and $145 billion globally by 2030 to 2040, with China's market expected to grow from 3.2 billion yuan in 2024 to over 5.5 billion yuan by 2027 [5] Summary by Sections Event Description - The first invasive BCI clinical trial in China was conducted by the Chinese Academy of Sciences and Fudan University, demonstrating significant advancements in BCI technology [5] - The trial involved a male subject who regained control over a computer touchpad after 2-3 weeks of training, showcasing the potential of BCI technology for improving the quality of life for patients with spinal cord injuries and amputations [5] Market Dynamics - The rapid progress in overseas BCI technology has garnered significant market attention, with companies like Neuralink and Regenative Medicine leading advancements [5] - The BCI market is expected to expand rapidly, driven by technological breakthroughs in medical rehabilitation [5] Investment Opportunities - Three main investment lines are suggested: 1. Domestic mapping of advanced overseas invasive BCI industry chains 2. Non-invasive BCI products in consumer scenarios 3. Downstream application targets related to BCI technology [5]